The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
India plays a critical role in Bristol Myers Squibb’s global strategy
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The company operates a chain of mid-sized multi-speciality hospitals
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Subscribe To Our Newsletter & Stay Updated
